Press Release Summary:
Featuring ultrasonic hand piece and small fluid delivery system, Generation 1.75 SonoPrepÂ® Device is ergonomic and portable with replaceable battery and digital display that monitors operation. Employing low-frequency ultrasound to penetrate skin's outermost layer, device makes skin permeable for up to 24 hours for continuous non-invasive diagnostics such as glucose monitoring and transdermal drug delivery.
Original Press Release:
Sontra Medical Introduces Generation 1.75 SonoPrep®Skin Permeation Device
FRANKLIN, Mass., Feb. 7 -- Sontra Medical Corporation (NASDAQ:SONT) announced today that it has introduced its Generation 1.75 SonoPrep(R) skin permeation device for topical lidocaine delivery. The upgraded device has a new and improved ultrasonic hand piece and fluid delivery system that is much smaller, simpler and less expensive to manufacture. The new hand piece also will be incorporated into the 2nd generation SonoPrep skin permeation device scheduled to be introduced in May 2006. The 2nd Generation SonoPrep device is more portable with improved ergonomics, a replaceable battery, and a digital display that monitors operation. "The initial response from intravenous and pediatric nurses has been very positive," stated Barry Marston, Sontra's Vice President of Sales and Marketing. "The practitioners appreciate the smaller, more ergonomic hand piece that is easier to apply and more comfortable for the patients."
The SonoPrep ultrasonic skin permeation employs low frequency ultrasound to penetrate the skin's outermost layer, the stratum corneum. This simple and fast (average 15 second) treatment creates an imperceptible window through the skin that enables molecules to pass through with 100 times greater efficiency than intact skin. The SonoPrep ultrasonic skin permeation device makes the skin permeable for up to twenty-four hours for continuous non-invasive diagnostics such as glucose monitoring and transdermal drug delivery.
About Sontra Medical Corporation (http://www.sontra.com/)
Sontra Medical Corporation is a technology leader in transdermal science. Sontra's SonoPrep ultrasound-mediated skin permeation technology combined with technical competencies in transdermal drug formulation, delivery systems and biosensors is creating a new paradigm in transdermal drug delivery and diagnosis. The SonoPrep technology is being developed for several billion dollar market opportunities, including continuous glucose monitoring and the transdermal delivery of large molecule drugs and vaccines. Sontra is currently marketing the SonoPrep device and procedure tray for use with topical lidocaine to achieve rapid (within five minutes) skin anesthesia.
CONTACT: Sean Moran, CFO of Sontra Medical, +1-508-530-0334